机构:[1]Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.[2]Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York.[3]Save Sight Institute, Faculty of Health and Medicine, The University of Sydney, Sydney Australia.[4]Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.[5]Departments of Ophthalmology and Visual Science, Neurology & Neurosurgery, McGill University, Montreal, Canada.[6]Department of Clinical Neurosciences, University of Calgary, Calgary, Canada.
Supported by the Neuro-Ophthalmology Research Fund, Department of
Neurology, Icahn School of Medicine at Mount Sinai, New York, New
York.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|1 区医学
小类|1 区眼科学
最新[2023]版:
大类|1 区医学
小类|1 区眼科学
第一作者:
第一作者机构:[1]Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.[2]Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York.[*1]Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, 1 Gustave Levey Place, New York, NY 10029.
通讯作者:
通讯机构:[1]Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.[2]Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York.[*1]Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, 1 Gustave Levey Place, New York, NY 10029.
推荐引用方式(GB/T 7714):
Kupersmith Mark J,Fraser Clare L,Morgenstern Rachelle,et al.Ophthalmic and Systemic Factors of Acute Nonarteritic Anterior Ischemic Optic Neuropathy in the Quark207 Treatment Trial[J].Ophthalmology.2024,doi:10.1016/j.ophtha.2024.01.011.
APA:
Kupersmith Mark J,Fraser Clare L,Morgenstern Rachelle,Miller Neil R,Levin Leonard A&Jette Nathalie.(2024).Ophthalmic and Systemic Factors of Acute Nonarteritic Anterior Ischemic Optic Neuropathy in the Quark207 Treatment Trial.Ophthalmology,,
MLA:
Kupersmith Mark J,et al."Ophthalmic and Systemic Factors of Acute Nonarteritic Anterior Ischemic Optic Neuropathy in the Quark207 Treatment Trial".Ophthalmology .(2024)